Review article · 2026 · Open access
CCR5 as a Therapeutic Target in HIV Disease: From CRISPR/Cas9 Gene Editing to Maraviroc-Mediated Inhibition
Viruses, 18(9), 972 · Published 3 September 2026 · DOI 10.3390/v18090972
In brief
“CCR5 as a Therapeutic Target in HIV Disease: From CRISPR/Cas9 Gene Editing to Maraviroc-Mediated Inhibition” is a 2026 review article by Uzair Iqbal and 4 co-authors, published in Viruses. OpenAlex counts 0 citations as of 19 November 2026. It is open access under a CC BY licence: the full text is free to read at Viruses.
- Citations
- 0
- References
- 98
- Authors
- 5
Abstract
The C-C chemokine receptor type 5 (CCR5) is the principal co-receptor for R5-tropic HIV-1 and remains one of the most promising therapeutic targets in the pursuit of an HIV cure. The discovery that individuals carrying the naturally occurring CCR5Δ32 mutation exhibit marked resistance to HIV infection established the foundation for both genetic and pharmacological approaches to CCR5 inhibition. This review summarizes recent advances in CCR5-targeted therapies with a focus on CRISPR/Cas9-mediated gene editing and maraviroc-mediated receptor blockade. We discuss the molecular mechanisms, preclinical evidence and emerging clinical data supporting CRISPR-based CCR5 disruption, including multiplex editing strategies designed to overcome viral tropism switching. We also examine the evolving role of maraviroc beyond viral entry inhibition, highlighting its immunomodulatory effects, potential latency-reversing activity and applications in graft-versus-host disease and cancer. Together, these complementary strategies underscore the potential of CCR5-targeted interventions as integral components of future combination therapies aimed at achieving durable HIV remission or functional cure.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Iqbal, U., Khalid, K., Shaltout, M., Yükselten, Y., & Sutton, R. E. (2026). CCR5 as a Therapeutic Target in HIV Disease: From CRISPR/Cas9 Gene Editing to Maraviroc-Mediated Inhibition. Viruses, 18(9), 972. https://doi.org/10.3390/v18090972
MLA 9
Iqbal, Uzair, et al. “CCR5 as a Therapeutic Target in HIV Disease: From CRISPR/Cas9 Gene Editing to Maraviroc-Mediated Inhibition.” Viruses, vol. 18, no. 9, 2026, p. 972. https://doi.org/10.3390/v18090972.
Chicago
Iqbal, Uzair, Khadija Khalid, Mohamed Shaltout, Yunus Yükselten, and Richard E. Sutton. 2026. “CCR5 as a Therapeutic Target in HIV Disease: From CRISPR/Cas9 Gene Editing to Maraviroc-Mediated Inhibition.” Viruses 18 (9): 972. https://doi.org/10.3390/v18090972.
Harvard
Iqbal, U. et al. (2026) ‘CCR5 as a Therapeutic Target in HIV Disease: From CRISPR/Cas9 Gene Editing to Maraviroc-Mediated Inhibition’, Viruses, 18(9), p. 972. doi:10.3390/v18090972.
IEEE
U. Iqbal, K. Khalid, M. Shaltout, Y. Yükselten, and R. E. Sutton, “CCR5 as a Therapeutic Target in HIV Disease: From CRISPR/Cas9 Gene Editing to Maraviroc-Mediated Inhibition,” Viruses, vol. 18, no. 9, p. 972, 2026, doi: 10.3390/v18090972.
BibTeX
@article{iqbal2026therapeutic,
title = {{CCR5 as a Therapeutic Target in HIV Disease: From CRISPR/Cas9 Gene Editing to Maraviroc-Mediated Inhibition}},
author = {Iqbal, Uzair and Khalid, Khadija and Shaltout, Mohamed and Yükselten, Yunus and Sutton, Richard E.},
journal = {Viruses},
year = {2026},
volume = {18},
number = {9},
pages = {972},
doi = {10.3390/v18090972},
url = {https://doi.org/10.3390/v18090972}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- CCR5
- HIV-1
- CCR5 delta32 mutation
- CRISPR/Cas9 genome editing
- maraviroc
- CCR5 inhibition
- HIV cure
- functional cure
Work with this paper
Most-cited papers in Immunology and Microbiology
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Ulrich K. Laemmli · Nature · 1970 · 249,784 citations
- Atherosclerosis — An Inflammatory DiseaseRussell Ross · New England Journal of Medicine · 1999 · 21,957 citations
- Continuous cultures of fused cells secreting antibody of predefined specificityGeorges Köhler, César Milstein · Nature · 1975 · 17,450 citations
- Inflammation and cancerLisa M. Coussens, Zena Werb · Nature · 2002 · 15,462 citations
- Dendritic cells and the control of immunityJacques Banchereau, Ralph M. Steinman · Nature · 1998 · 14,526 citations
Questions about this paper
How do I cite this paper in APA style?
Iqbal, U., Khalid, K., Shaltout, M., Yükselten, Y., & Sutton, R. E. (2026). CCR5 as a Therapeutic Target in HIV Disease: From CRISPR/Cas9 Gene Editing to Maraviroc-Mediated Inhibition. Viruses, 18(9), 972. https://doi.org/10.3390/v18090972
How many times has this paper been cited?
0 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Viruses: sign in and open the full text from this page.
Who wrote this paper?
Uzair Iqbal, Khadija Khalid, Mohamed Shaltout, Yunus Yükselten, Richard E. Sutton.
What is the DOI of this paper?
10.3390/v18090972, permanently at https://doi.org/10.3390/v18090972. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.